Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Body wash "meaningful" clinical use questioned by FDAers at HCCM symposium.

This article was originally published in The Tan Sheet

Executive Summary

ANTIMICROBIAL BODY WASH CLINICAL USEFULNESS QUESTIONED by David Bostwick, a clinical reviewer in the FDA's Division of Anti-infective Drug Products, at a June 2-3 symposium on the Healthcare Continuum Model held jointly by the Cosmetic, Toiletry & Fragrance Association and the Soap & Detergent Association in Washington, D.C. The model, proposed to FDA in 1995, is the industry's suggested regulatory scheme for antimicrobial ingredient-containing wash products used by consumers, food handlers and healthcare professionals ("The Tan Sheet" April 3, 1995, p. 15). The proposal, released in March 1995, responded to FDA's 1994 TFM that would set up a scheme for agency oversight of antimicrobial skin cleaners ("The Tan Sheet" June 27, 1994, pp. 7-10).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel